ATNM | tickerfilter.com

Fundamental analysis

38%

Profitability 35%

Dept financing 34%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.83%

1 Month

8.04%

3 Months

-16.55%

6 Months

-27.98%

1 Year

5.22%

2 Year

-82.51%

Key data

Stock price

$1.21

P/E Ratio

0.00

DAY RANGE

$1.19 - $1.22

EPS

-$1.26

52 WEEK RANGE

$1.02 - $2.41

52 WEEK CHANGE

$5.22

MARKET CAP

49.913 M

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-29-2025

BETA

3.22

PUBLIC FLOAT

AVERAGE 10 VOLUME

$97,871

AVERAGE 30 VOLUME

$113,159

Company detail

CEO: Sandesh Seth
Region: US
Website: actiniumpharma.com
Employees: 30
IPO year: 2011

Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Actinium Pharmaceuticals, Inc. focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning. The company also offers clinical and preclinical development programs that utilize multiple isotopes.

ATNM - Actinium Pharmaceuticals, Inc.